Interchangeability of hepatitis A vaccines

Interchangeability of hepatitis A vaccines - Interchangeability of hepatitis A vaccines

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009351

Enrollment

Registered

2012-11-19

Start date

2012-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis A

Interventions

Single dose of Havrix (1.0ml, IM)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: healty volunteer

Exclusion criteria

Exclusion criteria: acute febrile illness immunodeficiency allergy against vaccine contents pregnancy

Design outcomes

Primary

Measure	Time frame
Anti-HAV antibody: Anti-HAV antibody will be measured on days 0 and 28 after vaccination of Havrix.	—

Secondary

Measure	Time frame
Adverse event: Averse events will be documented by the subjects.	—

Countries

Japan

Contacts

Public ContactSHINJI FUKUSHIMA

Tokyo Medical University Hospital Travellers' Medical Center

fuku789@tokyo-med.ac.jp0353393726

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026